Assyro AI

FDA Orange Book · active-ingredient family

Triclofos sodium

Triclofos sodium is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:TRICLOS · NDA 016830

2

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · solution, tablet

ProductApplicantApplicationTEApproved
TRICLOSSANOFI AVENTIS USNDA 016830Approved Prior to Jan 1, 1982
TRICLOSSANOFI AVENTIS USNDA 016809Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Triclofos sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.